Results 81 to 90 of about 28,422 (269)

Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review

Journal of Clinical Medicine
Background: Bullous pemphigoid (BP) is an autoimmune disease characterized by the appearance of very pruritic subepidermal blisters. It appears mostly in the elderly and is associated with multiple comorbidities, which makes its management and treatment ...
Elena Granados-Betancort, M. Sánchez-Díaz, D. Muñoz‐Barba, Salvador Arias-Santiago   +3 more
semanticscholar   +1 more source

Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH)

Journal of Allergy and Clinical Immunology: Global, 2022
Background Food allergy is common and causes substantial morbidity and even mortality. Safe and effective treatments for food allergy would therefore be highly desirable, especially for individuals with multiple food allergies.
MD Robert A. Wood, MD Sharon Chinthrajah, MD Amanda K. Rudman Spergel, PhD Denise C. Babineau, MD Scott H. Sicherer, M. M. Edwin H. Kim, MD Wayne G. Shreffler, MD Stacie M. Jones, MD Donald Y. M. Leung, MD Brian P. Vickery, MD J. Andrew Bird, MD Jonathan M. Spergel, PhD Michael Kulis, MD Ahmar Iqbal, PhD Derrick Kaufman, MD Dale T. Umetsu, MD Monica Ligueros-Saylan, PhD Alkaz Uddin, MD Robert B. Fogel, MS Stephanie Lussier, RN Msn Kim Mudd, Mpa MS Fnp Julian Poyser, PhD Martin MacPhee, PhD Maria Veri, PhD Wendy Davidson, PharmD Mhs Sanaz Hamrah, PharmD Andrew Long, MD Alkis Togias   +27 more
semanticscholar   +1 more source

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim, Jacqueline Tu, Kelvin Truong, Gloria Fong, William Luu, Peter Barclay, Melanie Wong, Li‐Chuen Wong   +7 more
wiley   +1 more source

Omalizumab is ineffective in regulating proasthmatic serum cytokine and chemokine levels in nonresponders with high BMI

Journal of Allergy and Clinical Immunology: Global
Background: Omalizumab provides clinical benefits to a fraction of patients with asthma. It remains unclear why some patients do not respond to omalizumab therapy.
Agnes Yang, BS, Chao Gu, PhD, Katherine Upchurch, PhD, Adrien Caffiers, MS, Mark Millard, MD, Laurie Baert, PhD, HyeMee Joo, PhD, SangKon Oh, PhD   +7 more
doaj   +1 more source

Treatment of chronic urticaria with omalizumab: the experience of Hospital de Braga

Revista da Sociedade Portuguesa de Dermatologia e Venereologia, 2022
Introduction: Omalizumab is approved for the treatment of severe chronic spontaneous urticaria (CSU), unresponsive to quadruple doses of nonsedative H1 antihistamine.
Ana G. Lopes, Marianlie Navarro, Carmem Botelho, Maria J. Guimarães, Catarina Cerqueira, Joana Gomes, Celeste Brito   +6 more
doaj  

Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin [PDF]

, 2017
Background. Treatment with omalizumab, a humanized recombinant monoclonal anti-IgE antibody, results in clinical efficacy in patients with Chronic Spontaneous Urticaria (CSU). The mechanism of action of omalizumab in CSU has not been elucidated in detail.
Ashton-Chess, Joanna, Bauer, Andrea, Brehler, Randolf, Canvin, Janice, Erpenbeck, Veit J., Georgiou, Panayiotis, Gericke, Janine, Hillenbrand, Rainer, Jarvis, Philip, Kangas, Michael, Maurer, Marcus, Metz, Martin, Staubach, Petra   +12 more
core   +1 more source

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

Allergy, EarlyView.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau, Marcus Maurer, Adam Reich, Chia‐Yu Chu, Diana Deleanu, Gordon Sussman, Jorge Sanchez, Knut Brockow, Koremasa Hayama, Michihiro Hide, Mohamed Denguezli, Raisa Meshkova, Roberta F. J. Criado, Sarbjit Saini, Solange Valle, Eva Hua, Pengpeng Wang, Alis Burciu, Isabelle Indermuehle, Vineeth Varanasi, Yolandi Joubert, Thomas Severin, Manmath Patekar   +22 more
wiley   +1 more source

Neutralizing serum IgE upregulates CD88 and CRTH2 expression on basophils in patients with asthma

Journal of Allergy and Clinical Immunology: Global
Background: The cross-linking of FcεRI by IgE and allergen leads to the degranulation of basophils and mast cells, which can drive allergic reactions. Neutralizing IgE with omalizumab could thus offer clinical benefits to a subset of patients with asthma.
Agnes Yang, BS, Laurie Baert, PhD, Katherine Upchurch, PhD, Matthew Wiest, PhD, Jacob Turner, PhD, HyeMee Joo, PhD, Mark Millard, MD, SangKon Oh, PhD   +7 more
doaj   +1 more source

Serum free IgE guided dose reduction of omalizumab: a case report

Allergy, Asthma & Clinical Immunology, 2017
Background Omalizumab is a human IgG1 antibody against IgE used as a therapy for sever asthmatic patients with asthma. According to the guidelines of the Global Initiative for Asthma, omalizumab is an add-on drug at treatment step 5 that is used for ...
Yasuhiro Gon, Reiko Ito, Shuichiro Maruoka, Kenji Mizumura, Yutaka Kozu, Hisato Hiranuma, Yuko Iida, Sotaro Shikano, Shu Hashimoto   +8 more
doaj   +1 more source

Omalizumab for successful chemotherapy desensitisation: What we know so far

Clinical and Translational Allergy, 2021
Background Hypersensitivity reactions induced by chemotherapeutic drugs may influence the course of the oncologic disease by preventing doctors from prescribing first‐line therapy.
Roxana Silvia Bumbacea, Selda Ali, Sabina Loredana Corcea, Luiza Spiru, Cornelia Nitipir, Victor Strambu, Dragos Bumbacea   +6 more
doaj   +1 more source